Biogen Inc (BIIB)
157.84
-0.17
(-0.11%)
USD |
NASDAQ |
Nov 22, 16:00
157.92
+0.08
(+0.05%)
After-Hours: 16:49
Biogen Research and Development Expense (Quarterly): 542.70M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 542.70M |
| June 30, 2024 | 513.90M |
| March 31, 2024 | 452.90M |
| December 31, 2023 | 570.90M |
| September 30, 2023 | 736.30M |
| June 30, 2023 | 584.20M |
| March 31, 2023 | 570.60M |
| December 31, 2022 | 601.60M |
| September 30, 2022 | 549.20M |
| June 30, 2022 | 528.60M |
| March 31, 2022 | 551.70M |
| December 31, 2021 | 699.50M |
| September 30, 2021 | 702.40M |
| June 30, 2021 | 585.10M |
| March 31, 2021 | 514.20M |
| December 31, 2020 | 1.726B |
| September 30, 2020 | 1.141B |
| June 30, 2020 | 647.60M |
| March 31, 2020 | 476.30M |
| December 31, 2019 | 691.70M |
| September 30, 2019 | 540.40M |
| June 30, 2019 | 484.80M |
| March 31, 2019 | 563.70M |
| December 31, 2018 | 611.60M |
| September 30, 2018 | 507.90M |
| Date | Value |
|---|---|
| June 30, 2018 | 981.00M |
| March 31, 2018 | 496.70M |
| December 31, 2017 | 587.60M |
| September 30, 2017 | 446.40M |
| June 30, 2017 | 796.20M |
| March 31, 2017 | 423.40M |
| December 31, 2016 | 533.90M |
| September 30, 2016 | 529.00M |
| June 30, 2016 | 473.10M |
| March 31, 2016 | 437.30M |
| December 31, 2015 | 541.70M |
| September 30, 2015 | 519.90M |
| June 30, 2015 | 490.70M |
| March 31, 2015 | 460.50M |
| December 31, 2014 | 500.07M |
| September 30, 2014 | 417.17M |
| June 30, 2014 | 447.27M |
| March 31, 2014 | 528.88M |
| December 31, 2013 | 422.28M |
| September 30, 2013 | 410.02M |
| June 30, 2013 | 327.46M |
| March 31, 2013 | 284.34M |
| December 31, 2012 | 345.18M |
| September 30, 2012 | 304.22M |
| June 30, 2012 | 329.56M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
452.90M
Minimum
Mar 2024
1.726B
Maximum
Dec 2020
669.32M
Average
577.55M
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly and Co | 2.734B |
| Sage Therapeutics Inc | 54.58M |
| Pfizer Inc | 2.598B |
| Amgen Inc | 1.45B |
| Ionis Pharmaceuticals Inc | 219.76M |